← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $610B	3,267	+281	+9%	$284B
2	2 Merck MRK $358B	2,710	+151	+6%	$153B
3	3 Pfizer PFE $168B	2,676	+167	+7%	$137B
4	4 AbbVie ABBV $501B	2,599	+233	+10%	$128B
5	5 Bristol-Myers Squibb BMY $124B	2,362	+147	+7%	$103B
6	6 Amgen AMGN $235B	2,221	+93	+4%	$101B
7	7 Gilead Sciences GILD $195B	1,563	+26	+2%	$56.7B
8	8 Novartis NVS $286B	1,177	+59	+5%	$21.9B
9	9 Regeneron Pharmaceuticals REGN $82B	904	-3	-0.3%	$43.6B
10	10 GSK GSK $98.2B	819	-8	-1%	$11.1B
11	11 AstraZeneca AZN $259B	788	+64	+9%	$19.7B
12	12 DELISTED Exact Sciences EXAS	623	+106	+21%	$19.3B
13	13 Incyte INCY $23B	512	+11	+2%	$17.7B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	511	+76	+17%	$28.6B
15	15 Jazz Pharmaceuticals JAZZ $13.9B	437	+48	+12%	$8.69B
16	16 Guardant Health GH $22.3B	419	+73	+21%	$11.3B
17	17 Exelixis EXEL $15.6B	352	-16	-4%	$5.23B
18	18 Halozyme HALO $13.8B	343	+74	+28%	$5.82B
19	19 NeoGenomics NEO $2.22B	340	+46	+16%	$5.6B
20	20 Takeda Pharmaceutical TAK $62.1B	313	+2	+0.6%	$1.98B
21	21 Natera NTRA $58.3B	304	+51	+20%	$8.39B
22	MRTX 22 DELISTED Mirati Therapeutics, Inc. Common Stock MRTX	284	+59	+26%	$11.5B
23	23 DELISTED Blueprint Medicines BPMC	279	+42	+18%	$6.46B
24	24 Iovance Biotherapeutics IOVA $6.67B	269	+17	+7%	$6.9B
25	25 Qiagen QGEN $9.53B	269	+16	+6%	$6.46B